Another study (phase I) with a combination of polyclonal Tregs and low-dose IL-2 for the treatment of T1D was completed, indicating the role of IL-2 in the expansion of exogenously administered Tregs and, at the same time, of cytotoxic cells [135]. Here, IL2 is linked to type 1 diabetes mellitus.